An Improved Syngeneic Orthotopic Murine Model of Human Breast Cancer Progression

PURPOSE: Breast cancer drug development costs nearly $610 million and 37 months in preclinical mouse model trials with minimal success rates. Despite these inefficiencies, there are still no consensus breast cancer preclinical models. METHODS: Murine mammary adenocarcinoma 4T1-luc2 cells were implan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rashid, Omar M., Nagahashi, Masayuki, Ramachandran, Suburamaniam, Dumur, Catherine, Schaum, Julia, Yamada, Akimitsu, Terracina, Krista P., Milstien, Sheldon, Spiegel, Sarah, Takabe, Kazuaki
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176514/
https://ncbi.nlm.nih.gov/pubmed/25200444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3118-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars